Henan Cancer Hospital
π¨π³China
- Country
- π¨π³China
- Ownership
- Private
- Established
- 1977-01-01
- Employees
- -
- Market Cap
- -
Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT05545124
Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 219
- Registration Number
- NCT05495152
- Locations
- π¨π³
Henan Cancer Hospital, Zhengzhou, Henan, China
Clinical Study of Anlotinib Combined With Chemotherapy in the Treatment of Unresectable Advanced Desmoid Tumor
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05490667
- Locations
- π¨π³
Department of Bone and Soft Tissue ,Henan Cancer Hospital, Zhengzhou, Henan, China
Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05490485
- Locations
- π¨π³
Department of Bone and Soft Tissue ,Henan Cancer Hospital, Zhengzhou, Henan, China
Application of Painting Analysis and Psychotherapy in Children With Bone Tumors
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05475938
- Locations
- π¨π³
Department of Bone and Soft Tissue ,Henan Cancer Hospital, Zhengzhou, Henan, China
A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer
- First Posted Date
- 2022-07-26
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Henan Cancer Hospital
- Registration Number
- NCT05474690
- Locations
- π¨π³
Henan cancer hospital, Zhengzhou, Henan, China
Study on Clinical Features, Treatment Mode and Survival of Bone and Soft Tissue Tumors
Recruiting
- Conditions
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 6000
- Registration Number
- NCT05468970
- Locations
- π¨π³
Department of Bone and Soft Tissue ,Henan Cancer Hospital, Zhengzhou, Henan, China
PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05466474
- Locations
- π¨π³
Department of Bone and Soft Tissue ,Henan Cancer Hospital, Zhengzhou, Henan, China
Study on Clinical Features, Treatment Mode and Survival of Sarcoma
Recruiting
- Conditions
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 6000
- Registration Number
- NCT05453409
- Locations
- π¨π³
Department of Bone and Soft Tissue ,Henan Cancer Hospital, Zhengzhou, Henan, China
A Study on the Potential Benefit of Neoadjuvant Therapy for AGC Patients
- Conditions
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 54
- Registration Number
- NCT05442138
Β© Copyright 2024. All Rights Reserved by MedPath